Horizon Pharma

United States
Attalla, Alabama, United States, 60062

Company profile

Horizon Pharma company profile

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

Business identity

Contact email
[email protected]
Phone number
+353 1 772 2100
Operating status
Active
Company type
For Profit
Employee range
1,001-5,000 employees
Revenue range
$100M-$1B
Founded
2005-01-01, Year

Headquarters

Postal code
60062
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
17
Total equity funding
$2.2B
Last funding
Post IPO Equity / $963.5M / 2020-08-06
Last equity funding
Post IPO Equity / $963.5M
Investors
10
Lead investors
3
Founders
1
Articles
292
Exited on
2011-07-28

Founders and investors

Founders

George Tidmarsh

Lead investors

DeerfieldEssex Woodlands Healthcare PartnersScale Venture Partners

Investors

DeerfieldEssex Woodlands Healthcare PartnersKreos CapitalScale Venture PartnersSilicon Valley Bank